Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients

Nephrology Dialysis Transplantation

Volumn 13, Issue 10, 1998, Pages 2612-2616

  Venkat Raman, Gopalakrishnan ^a   Feehally, John ^b   Elliott, Henry L ^c   Griffin, Peter ^d   Moore, Richard J ^e   Olubodun, Joel O B ^f   Wilkinson, Robert ^f  

^a ST MARY S HOSPITAL   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d Cardiff Royal Infirmary   (United Kingdom)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^f FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Amlodipine; Cyclosporin A; Hypertension; Nifedipine; Post transplant; Renal transplantation

Indexed keywords

AMLODIPINE; CYCLOSPORIN A; NIFEDIPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AMLODIPINE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; HYPERTENSION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NIFEDIPINE; RENAL PLASMA FLOW; SINGLE-BLIND METHOD;

EID: 0031669530     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.10.2612     Document Type: Article

References (37)

1. Noble S, Markham A. CsA. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion based formulation (Neoral®). Drugs 1995; 50: 924-941
2. Ruggenenti P, Perico N, Mosconi L et al. Calcium channel blockers protect transplant patients from CsA induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-711
3. Textor SC, Burnett JC, Carlos Romero J et al. Urinary endothelin and renal vasoconstriction with CsA or FK 506 after liver transplantation Kidney Int 1995; 47: 1426-1433
4. Faulds D, Goa KL, Benfield P. CsA. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040
5. Raine AEG. Does antihypertensive therapy modify chronic allograft failure? Kidney Int 1995; 48 [Suppl 52]: S107-S111
6. Nayler WG. Amlodipine. Springer-Verlag, Berlin. 1993
7. Van der Schaaf MR, Hene RJ, Floor M et al. Hypertension after renal transplantation: calcium channel or converting enzyme blockade? Hypertension 1995; 25: 77-81
8. Sennesael JJ, Lamote JG, Violet I et al. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in CsA treated renal allograft recipients. Am J Kidney Dis 1996; 27: 701-708
9. Propper DJ, Whiting PH, Power DA et al. The effect of nifedipine on graft function in renal allograft recipients treated with CsA. Clin Nephrol 1989; 32: 62-67
10. Seccia TM, Vulpis V, Ricci S et al. Antihypertensive and metabolic effects of amlodipine in patients with non-insulin-dependent diabetes mellitus. Clin Drug Invest 1995; 9: 16-21
11. Mimran A, Insua A, Ribstein J et al. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care 1988; 11: 850-853
12. Cantarovitch M, Hiesse C, Lokiec F et al. Confirmation of the action of CsA and the calcium channel blocker nicardipine in renal transplant patients. Clin Nephrol 1987; 28: 190-193
13. Kronbach T, Fischer V, Meyer UA. CsA metabolism in human liver: Identification of a cytochrome P-450 III gene family as a major CsA metabolising enzyme which explains interactions of CsA with other drugs. Clin Pharmacol Ther 1988; 43: 630-635
14. Bourbigot B, Guiserix J, Airiau J et al. Nicardipine increases CsA blood levels. Lancet 1986; 1: 1447
15. Ladefoged SD, Andersen CB. Calcium channel blockers in kidney transplantation. Clin Transplant 1994; 8: 128-133
16. Carozzi S, Nasini MG, Pietrucci A et al. Immunosuppressive effects of different calcium channel blockers in human kidney allografts. Transplant Proc 1995; 27: 1054-1057
17. Pocock SJ. Clinical Trials. John Wiley & Sons 1984; 84-87
18. Jones B, Kenward MG. The design and analysis of crossover trials. Chapman & Hall, 1989; 60-67
19. Chung M, Reitberg DP, Gaffney M, Singleton W. Clinical pharmocokinetics of nifedipine gastrointestinal transport system: a controlled release formulation of nifedipine. Hosp Formul 1990; 25: 15-19
20. Ferrucci A. Amlodipine and nifedipine GITS: 24 HR antihypertensive profile. J Hypertens 1994; 12 [Suppl 3]: Abstract, 1448
21. Detry J-MR, Block P, DeBacker G, Degaute J-P. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur J Clin Pharmacol 1995; 47: 477-481
22. Kaplan NM. Ethnic aspects of hypertension. Lancet 1994; 344: 450-452
23. Abu-Romeh SH, El-Khatib D, Rashid A et al. Comparative effects of enalapril and nifedipine on renal haemodynamics in hypertensive renal allograft recipients. Clin Nephrol 1992; 37: 183-188
24. Mourad G, Ribstein J, Mimran A. Converting enzyme inhibitor versus calcium antagonist in CsA treated renal transplants. Kidney Int 1993; 43: 419-425
25. Toupance O, Lavaud S, Canivet E et al. Antihypertensive effects of amlodipine and lack of interference with CsA metabolism in renal transplant recipients. Hypertension 1994; 24: 297-300
26. Venkat-Raman G, Feehally MJ, Griffin P, Wilkinson R. Renal and haemodynamic effects of amlodipine in cyclosporin treated renal transplant patients Nephrology 1997; 3 [Suppl 1]: p. 993
27. Martinez AM, Heubi TR. Welch WF et al. Role of calcium channel blockers (amlodipine) in reversing CsA or tacrolimus induced nephrotoxicity in pediatric orthotopic liver transplant (OLT) recipients. Gastroenterology 1996; 10 (4) [Suppl 2]: AASLD Abstract 1259
28. Corradi L, Lusardi P, Pasotti A et al. Effects of amlodipine vs fosinopril on microalbuminuria in elderly hypertensive patients with type II diabetes. Am J Hypertens 1996; 9: 152A
29. Corradi L, Zoppi A, Poletti L et al. Effect on microalbuminuria of long term treatment with amlodipine and enalapril in hypertensives with type II diabetes. 15th Scientific Meeting of the International Society of Hypertension. J Hypertens 1994; 12 [Suppl 3]: 156
30. Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-222
31. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in normotensive diabetic patients with microalbuminuria. Br Med J 1991; 302: 210-216
32. Chan JCN, Cockram CS, Nicholls MG et al. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. Br Med J 1992; 305: 981-985
33. Romero R, Salinas I, Lucas A et al. Comparative effects of captopril versus nifedipine on proteinuria and renal function in type 2 diabetic patients. Diabetes Res Clin Pract 1992; 17: 191-198
34. Reams GP. Do calcium channel blockers have renal protective effects? Drugs Aging 1994; 5: 263-287
35. Grezard O, Sharobeem R, Al Najjar A. Effect of amlodipine on CsA pharmacokinetics. Am J Hypertens 1993; 6: A1038
36. Sketris IS, Methot ME, Nicol D et al. Effect of calcium channel blockers on CsA clearance and use in renal transplant patients. Ann Pharmacother 1994; 28: 1227-1231
37. Crocker JFS, Renton KW, Le Vatte, TL et al. The interaction of the calcium channel blockers verapamil and nifedipine with CsA in pediatric renal transplant patients. Pediatr Nephrol 1994; 8: 408-411